Kanchanjanga Medipharma Profile
Key Indicators
- Authorised Capital ₹ 1.01 Cr
as on 21-12-2024
- Paid Up Capital ₹ 1.00 Cr
as on 21-12-2024
- Company Age 12 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 23.38%
(FY 2022)
- Profit 9.62%
(FY 2022)
- Ebitda -235.28%
(FY 2022)
- Net Worth 1.03%
(FY 2022)
- Total Assets 24.48%
(FY 2022)
About Kanchanjanga Medipharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.01 Cr and a paid-up capital of Rs 1.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Nand Jalan, Tapan Saha, Alok Paul, and Four other members serve as directors at the Company.
- CIN/LLPIN
U24233WB2012PTC184337
- Company No.
184337
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Aug 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Darjiling, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Kanchanjanga Medipharma?
Board Members(7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Alok Paul  | Director | 02-Aug-2012 | Current |
| Nand Jalan | Director | 02-Aug-2012 | Current |
| Tapan Saha | Director | 02-Aug-2012 | Current |
| Pradip Paul | Director | 25-Jun-2013 | Current |
| Dilip Saha | Director | 25-Jun-2013 | Current |
| Uttam Saha | Director | 25-Jun-2013 | Current |
Financial Performance of Kanchanjanga Medipharma.
Kanchanjanga Medipharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 23.38% increase. The company also saw a slight improvement in profitability, with a 9.62% increase in profit. The company's net worth moved up by a moderate rise of 1.03%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kanchanjanga Medipharma?
In 2020, Kanchanjanga Medipharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Get Well Medipharma Private LimitedActive 14 years 10 monthsNand Jalan, Tapan Saha and 1 more are mutual person
- K. J. Sales & Services Private LimitedActive 6 months 17 days
Nand Jalan, Tapan Saha and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Kanchanjanga Medipharma?
Kanchanjanga Medipharma has a workforce of 55 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kanchanjanga Medipharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kanchanjanga Medipharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
